Neurocrine Biosciences clinical trials

The registry lists 121 studies whose lead sponsor is Neurocrine Biosciences or one of 4 companies grouped under it. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 121. Browse all 121 →

• A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT07196501Phase 3
• Observational Study of VYKAT™ XR in Patients With Prader-Willi SyndromeEnrolling by invitationNCT07450664

  Sponsor listed in the registry: Soleno Therapeutics, Inc. · First submitted before Soleno Therapeutics, Inc. became part of Neurocrine Biosciences

• Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)Not yet recruitingNCT07850739Phase 2
• An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current ManiaRecruitingNCT07288320Phase 2
• NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaRecruitingNCT07105098Phase 3
• Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaRecruitingNCT07227818Phase 3
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaRecruitingNCT07114874Phase 3
• Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase InhibitorNot yet recruitingNCT07832383Phase 2
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingNCT07105111Phase 4
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years OldRecruitingNCT07536269Phase 2

  Sponsor listed in the registry: Neurocrine Switzerland GmbH

• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06911112Phase 3
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06963021Phase 3
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06966401Phase 3
• Evaluation of NBI-1117570 in Inpatient Adults With SchizophreniaRecruitingNCT07288333Phase 2
• Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive DyskinesiaRecruitingNCT07365462Phase 2
• Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in CanadaEnrolling by invitationNCT06312189Phase 3
• NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaRecruitingNCT06963034Phase 3
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06786624Phase 3
• Open-Label Extension Study of DCCR in Patients With Prader-Willi SyndromeCompletedNCT05701774Phase 3

  Sponsor listed in the registry: Soleno Therapeutics, Inc. · First submitted before Soleno Therapeutics, Inc. became part of Neurocrine Biosciences

• An Open-Label Study of Diazoxide Choline in Patients With Genetic ObesitiesWithdrawnNCT05532020Phase 2

  Sponsor listed in the registry: Soleno Therapeutics, Inc. · First submitted before Soleno Therapeutics, Inc. became part of Neurocrine Biosciences

• Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal HyperplasiaCompletedNCT05063994Phase 3

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAHCompletedNCT03062280Phase 3

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• An Investigational Study of HydrocortisoneCompletedNCT01960530Phase 1

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Extension Study for Patients Entered Into Study Infacort 003CompletedNCT02733367Phase 3

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Comparison of Pharmacokinetics of Infacort® Versus Immediate-release HydrocortisoneCompletedNCT02777268Phase 1

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAHCompletedNCT01735617Phase 2

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal HyperplasiaCompletedNCT02716818Phase 3

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Treatment of Adrenal Insufficiency in ChildrenCompletedNCT02720952Phase 3

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• A Study of Chronocort® Versus Cortef ® in Healthy Adult Male SubjectsCompletedNCT03343327Phase 1

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• An Open Label Study in Healthy Volunteers to Compare Chronocort® to HydrocortisoneCompletedNCT03019614Phase 1

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement TherapyWithdrawnNCT03532022Phase 3

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral AdministrationCompletedNCT03178214Phase 1

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal InsufficiencyCompletedNCT05222152Phase 2

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female SubjectsCompletedNCT03311932Phase 1

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Study to Compare DITEST to Testosterone Undecanoate in Adult Men With HypogonadismCompletedNCT02966652Phase 1

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort FormulationsCompletedNCT03051893Phase 1

  Sponsor listed in the registry: Neurocrine UK Limited · First submitted before Neurocrine UK Limited left Neurocrine Biosciences

• Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years OldActive, not recruitingNCT07187375Phase 2

  Sponsor listed in the registry: Neurocrine Switzerland GmbH

• A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive DisorderCompletedNCT06267846Phase 2
• Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseCompletedNCT04400331Phase 3
• Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEETerminatedNCT05226780Phase 2
• Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal HyperplasiaActive, not recruitingNCT04490915Phase 3
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyCompletedNCT05206513Phase 3
• Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepTerminatedNCT05301894Phase 2
• Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaCompletedNCT05110157Phase 3
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedNCT05859698Phase 4
• Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)TerminatedNCT04873869Phase 2
• Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepCompletedNCT04625101Phase 2
• Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With SchizophreniaCompletedNCT05545111Phase 2
• Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With SchizophreniaTerminatedNCT05182476Phase 2
• Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)Active, not recruitingNCT04806451Phase 3